References - Signal Processing in MRS with Biomedical Applications - page 436

[417] GarciaSegura, J.M., SanchezChapado, M., Ibarburen, C., Viano, J.,
Angulo, J.C., Gonzalez J., and RodriguezVallejo, J.M., In vivo proton
magnetic resonance spectroscopy of disease prostate: spectroscopic
features of malignant versus benign pathology, Magn. Reson. Imag.,
17, 755 - 765, 1999.
[418] Yu, K.K., Scheidler, J., Hricak, H., Vigneron, D.B., Zaloudek, C.J.,
Males, R.G., Nelson, S.J., Carroll, P.R., and Kurhanewicz, J.,
Prostate cancer: prediction of extracapsular extension with endorectal
MR imaging and threedimensional proton MR spectroscopic imaging,
Radiology, 213, 481 - 488, 1999.
[419] Wu, X., Dibiase, S.J., Gullapalli, R., and Yu, C.X., Deformable image
registration for the use of magnetic resonance spectroscopy in prostate
treatment planning, Int. J. Radiat. Oncol. Biol. Phys., 58, 1577 -
1583, 2004.
[420] Chen, M., Dang, H.D., Wang, J.Y., Zhou, C., Li, S.Y., Wang, W.C.,
Zhao, W.F., Yang, Z.H., Zhong, C.Y., and Li, G.Z., Prostate cancer
detection: comparison of T2weighted imaging, diffusionweighted
imaging, proton magnetic resonance spectroscopic imaging, and the
three techniques combined, Acta Radiol., 49, 602 - 610, 2008.
[421] Cirillo, S., Petracchini, M., Della Monica, P., Gallo, T., Tartaglia, V.,
Vestita, E., Ferrando, U., and Regge, D., Value of endorectal MRI and
MRS in patients with elevated prostatespecific antigen levels and
previous negative biopsies to localize peripheral zone tumors, Clin.
Radiol., 63, 871 - 979, 2008.
[422] Lawrentschuk, N., and Fleshner, N., The role of magnetic resonance
imaging in targeting prostate cancer in patients with previous negative
biopsies and elevated prostatespecific antigen levels, Br.J. Urol. Int.,
103, 730 - 733, 2009.
[423] Kumar, R., Nayyar, R., Kumar, V., Gupta, N., Hemal, A.,
Jagannathan, R., Dattagupta, S., and Thulkar, S., Potential of
magnetic resonance spectroscopic imaging in predicting absence of
prostate cancer in men with serum prostatespecific antigen between 4
and 10 ng/ml: a followup study, Urology, 72, 859 - 863, 2008.
[424] Cabrera, A.R., Coakley, F.V., Westphalen, A.C., Lu, Y., Zhao, S.,
Shinohara, K., Carroll, P.R., and Kurhanewicz, J., Prostate cancer: is
inapparent tumor at endorectal MR and MR spectroscopic imaging a
favorable prognostic finding in patients who select active surveillance?
Radiology, 247, 444 - 450, 2008.
[425] ShuklaDave, A., Hricak, H., and Scardino, P.T., Imaging lowrisk
prostate cancer, Curr. Opin. Urol., 18, 78 - 86, 2008.